New way to recombinantly express specific tumor associated epitopes on the surface of T cell works as immune Trojans called CAR s or simply Chimeric Antigen Receptors. CAR s are recombinant protein like monoclonal antibodies. This technology is promising and a targeted therapy with great enthusiasm. CAR- T cell have shown potential application against the resistant, metastatic cancer. The review focus on understanding the CAR therapy, strategies, challenges and its imaginable and futuristic approach.
Impact Factor
2022: 6.012
This work is licensed under a